CRISPR Therapeutics AG (CRSP) stock overview

CRISPR Therapeutics AG

CRSP

$48.15

+2.47%

2026-07-21 20:00:01+$1.16

Healthcare

Biotechnology

NASDAQ

Active Trading

CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its ...

Price Action of CRSP

High:—

Low:—

52W High:$78.48

52W Low:$44.12

Range 6.5h

Fundamental Analysis of CRSP

Loading analysis...

Profitability

Net MarginN/A

Operating MarginN/A

Valuation

P/E RatioNaNx

Current RatioN/A

Efficiency

ROE-31.20%

ROA-14.10%

Key Products & Solutions of CRSP

No product data available

Financial Statements of CRSP

5Y Trend (Revenue, Earnings, FCF)

Metric	Latest	YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.	QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).	—	—	—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.	—	—	—
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.	—	—	—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).	—	—	—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.	—	—	—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.	—	—	—
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.	—	—	—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.	—	—	—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.	—	—	—
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.	—	—	—

Actual vs Estimate

A —Q —

Metric	Annual (A vs E)	Annual Surprise	Quarter (A vs E)	Quarter Surprise
EPS Surprise	—	—	—	—
Revenue Surprise	—	—	—	—

CEO Profile of CRSP

CRSP

Generating AI CEO profile...

Key Risk

No major risk extracted yet.

Key Tailwind

No major tailwind extracted yet.

Leadership Team of CRSP

10 executives

Name	Title	Compensation	Gender	Year Born	Status
Samarth Kulkarni	Chief Executive Officer & Chairman	USD 1,434,715	—	1978	Active
Naimish Patel	Chief Medical Officer	USD 858,490	—	1972	Active
James R. Kasinger	General Counsel & Secretary	USD 780,577	Male	1972	Active
Raju Yashaswi Prasad	Chief Financial Officer	USD 779,557	—	1984	Active
Shaun Foy	Co-Founder	—	Male	—	Active
Chad A. Cowan	Scientific Founder	—	—	1972	Active
Craig C. Mello	Co-Founder & Scientific Advisory Board Member	—	—	—	Active
Daniel G. Anderson	Co-Founder & Scientific Advisory Board Member	—	—	1970	Active
Emmanuelle Marie Charpentier	Co-Founder & Scientific Advisory Board Member	—	—	—	Active
Matthew Porteus	Co-Founder & Scientific Advisory Board Member	—	—	1965	Active

CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. reduced its stake in CRISPR Therapeutics AG ($CRSP) by 5.3% in the first quarter of 2026, selling over 104,000 shares to hold 1.85 million shares valued at approximately $88.2 million. Despite this reduction and the company reporting a Q1 EPS of -$1.28 and low revenue, analyst sentiment remains cautiously positive with a "Moderate Buy" consensus rating and an average price target of $67.78. Institutional investors collectively own 69.20% of the company's stock.

Yahoo Finance7/10/2026Neutral (-0.071)

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

CRISPR Therapeutics AG (CRSP) saw its stock dip by 5.31% while the broader market gained. Despite the recent dip, the company's shares have appreciated by 12.16% over the past month, outperforming its sector and the S&P 500. Analysts anticipate significant year-over-year growth in both earnings and revenue for CRSP's upcoming report, with the company currently holding a Zacks Rank of #3 (Hold).

The Globe and Mail7/9/2026Neutral (0.002)

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Bank of America Securities analyst Alec Stranahan reaffirmed a Buy rating for Crispr Therapeutics AG (CRSP) with an $83 price target. This follows a similar Buy rating by Piper Sandler. The company reported a quarterly revenue of $1.46 million and a GAAP net loss of $122.93 million in its latest earnings report.

The Globe and Mail7/8/2026Bullish (0.546)

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP) with an $83.00 price target. This follows a similar reaffirmation by Piper Sandler with a $110.00 price target. The company reported first-quarter revenue of $1.46 million and a GAAP net loss of $122.93 million, an improvement from the previous year.

Yahoo Finance7/8/2026Neutral (0.105)

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

This article compares CRISPR Therapeutics and Viking Therapeutics, two biotechnology companies with different focuses: gene-editing and weight loss. While CRISPR Therapeutics has already launched its gene therapy Casgevy, Viking Therapeutics is a clinical-stage company with no current revenue but promising drugs in its pipeline. The analysis suggests CRISPR Therapeutics is a better buy in 2026 due to its commercialization success, despite both companies operating in high-potential markets.

Historical Employee Count of CRSP

Current

420

Change

+6.87%

Minimum

393

Maximum

473

Recent Filings

Report Date	Employees	Form Type	Filing Date	SEC Filing
Dec 31, 2025	420	10-K	Feb 12, 2026	View
Dec 31, 2024	393	10-K	Feb 11, 2025	View
Dec 31, 2023	407	10-K	Feb 21, 2024	View
Dec 31, 2022	458	10-K	Feb 21, 2023	View
Dec 31, 2021	473	10-K	Feb 15, 2022	View

About Us•Privacy Policy•Terms of Service•Join our Slack

No matching stocks found

No matching stocks found

CRISPR Therapeutics AG

Price Action of CRSP

Company Overview of CRSP

Fundamental Analysis of CRSP

Key Metrics of CRSP

Financial Highlights of CRSP

Key Products & Solutions of CRSP

Financial Statements of CRSP

CEO Profile of CRSP

Leadership Team of CRSP

Recent News of CRSP

CRISPR Therapeutics AG $CRSP Position Reduced by Sumitomo Mitsui Trust Group Inc.

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

Bank of America Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)

CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?

Historical Employee Count of CRSP

Recent Filings